Phaseline

Targets › TYR1R

TYR1R: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Ophthalmology; next expected readout Apr 2027.

Open in Phaseline: the race on TYR1R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NYU Langone HealthTRYPTYR (Acoltremon ophthalmic solution 0.003%)
TYR1 receptor agonist
TYR1RPhase 4Dry Eye Disease (DED)Apr 2027

Conditions

Dry Eye Disease (DED) (1)

Modalities

small molecule (1)

Companies

NYU Langone Health (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.